Glycine-β-muricholic Acid (Synonyms: Gly-MCA, GβMCA) |
| رقم الكتالوجGC40911 |
Glycine-β ؛ -muricholic Acid ، حمض الصفراء ، هو مثبط لمستقبلات Farnesoid X القوية ، السمور ، الانتقائي للأمعاء والنشط بيولوجيًا عن طريق الفم (FXR) والذي قد يكون مرشحًا لعلاج الاضطرابات الأيضية.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 66225-78-3
Sample solution is provided at 25 µL, 10mM.
Glycine-β-muricholic Acid is an effective, stable, and arginine-selective oral bioactive FXR inhibitor. It is the glycine-bound form of the murine primary bile acid β-muricholic acid. FXR is an important sensor and regulator of bile acid, lipid, and glucose metabolism [1]. Glycine-β-muricholic Acid can be used in studies of metabolic disorders [2].
In vivo, Glycine-β-muricholic Acid (10 and 50mg/kg; 5 weeks; oral) significantly reduced the absolute fat mass and fat-to-weight ratio of obese and insulin-resistant mice induced by HFD, as well as insulin resistance and hepatic steatosis, with a significant decrease in liver lipid droplets [1]. Glycine-β-muricholic Acid (10mg/kg/day; 23d once every 2 days; Gavage) treatment significantly reduced the protective effect of Lactobacillus reuteri on alcohol-induced lipid accumulation in the liver of mice. Lactobacillus reuteri and its metabolites may regulate liver inflammation through the FXR signaling regulatory axis [3].
References:
[1] Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
[2] Hasan M N, Wang H, Luo W, et al. Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice[J]. Journal of Lipid Research, 2024, 65(10).
[3] Cheng Y, Xiang X, Liu C, et al. Transcriptomic analysis reveals Lactobacillus reuteri alleviating alcohol-induced liver injury in mice by enhancing the farnesoid X receptor signaling pathway[J]. Journal of agricultural and food chemistry, 2022, 70(39): 12550-12564.
| Animal experiment [1]: | |
Animal models | C57BL/6N mice |
Preparation Method | For thermal neutral temperature exposure experiments, male 6-week-old C57BL/6N mice fed a HFD were orally administered with vehicle (control pills) or Glycine-β-muricholic Acid (0.25mg per pill per day, dose10mg kg−1) at 29.5°C for 2 weeks. For cold stimulation experiments, male 6-week-old C57BL/6N mice fed a HFD were orally administered with vehicle (control pills) or Glycine-β-muricholic Acid (0.25mg per pill per day, dose 10mg kg−1) at 22°C for 5 days and then acutely moved to 5°C for another 1 day. All mice were randomly assigned to experimental groups and the groups showed no difference in body weight gain before treatment. |
Dosage form | 10mg/kg/day for 5 days and two weeks; p.o. |
Applications | A short-duration 5-day treatment with Glycine-β-muricholic Acid specifically increases beige fat thermogenesis and energy expenditure before body weight change. |
References: | |
| Cas No. | 66225-78-3 | SDF | |
| المرادفات | Gly-MCA, GβMCA | ||
| Chemical Name | N-[(3α,5β,6β,7β)-3,6,7-trihydroxy-24-oxocholan-24-yl]-glycine | ||
| Canonical SMILES | O[C@@H]1CC[C@@]2(C)[C@@]([C@H](O)[C@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCC(O)=O)=O)([H])C1 | ||
| Formula | C26H43NO6 | M.Wt | 465.6 |
| الذوبان | 20mg/mL in ethanol, or in DMSO, 20mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1478 mL | 10.7388 mL | 21.4777 mL |
| 5 mM | 429.6 μL | 2.1478 mL | 4.2955 mL |
| 10 mM | 214.8 μL | 1.0739 mL | 2.1478 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *